Business
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
HAYWARD, Calif., January 09, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026.
About this update from Hyperfine, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/53d3d23b3d1a2c0bd9f45fcf2cd44928"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zp9LduD87mboHqo5fT7zzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/53d3d23b3d1a2c0bd9f45fcf2cd44928","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.aY3lYYp7VLl8fw9GLb_jA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/53d3d23b3d1a2c0bd9f45fcf2cd44928","width":1024,"height":512}},"lazy":false},{"type":"text","content":"HAYWARD, Calif., January 09, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026.","length":338,"tagName":"p"},{"type":"text","content":""We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional markets with our patient-first mission."","length":470,"tagName":"p"},{"type":"text","content":"Mrs. Sainz brings over three decades of experience in healthcare technology, including 18 years in CEO roles leading publicly traded companies and venture-backed startups. Currently, she serves as President and CEO of Hyperfine, Inc. (NASDAQ: HYPR), a medical technology company with a commercial stage portable brain MRI system. Previously, she served as President and CEO of Aegea Medical, a VC-backed women’s health company, President and CEO of CardioKinetix Inc., a VC-backed company in interventional heart failure therapy, and as President and CEO of Concentric Medical, a VC-backed stroke thrombectomy company. Prior to her CEO roles, Mrs. Sainz served in various leadership capacities at Guidant C...